Disease Modification

2 issues on this topic, newest first.

Issue 3 Aug 30, 2026 7 min read

The bigger trial said no. Then the paper was flagged.

A large trial of exenatide — the GLP-1 drug the field had pinned real hope on — found no benefit in Parkinson's. Eighteen months later the paper was placed under an expression of concern after inspectors found serious problems at one of its hospitals. Both facts matter.

Study: The Lancet

Read the summary

Issue 2 Aug 23, 2026 5 min read

A diabetes drug that seemed to slow Parkinson's down

In a year-long French trial, people with early Parkinson's who took the diabetes drug lixisenatide did not get worse, while those on placebo did. The gap was small, the side effects were not, and the result raised more questions than it settled.

Study: New England Journal of Medicine

Clinical Trials Drug Repurposing Disease Modification

Read the summary